Hanover, NH, United States of America

Mark A Israel


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mark A Israel: Innovator in Glioma Treatment

Introduction

Mark A Israel is a prominent inventor based in Hanover, NH (US). He has made significant contributions to the field of medical research, particularly in the treatment of gliomas. With a total of 2 patents, his work focuses on innovative approaches to combat glial tumors.

Latest Patents

Israel's latest patents include groundbreaking inventions aimed at treating gliomas. The first patent, titled "MicroRNA-10 antagonists and MicroRNA-10 targets for use in the treatment of a glioma," involves microRNA-antagonists and activators of homeobox D10 protein, Zinc finger, MYND domain containing 11 protein, or RB1-inducible coiled-coil 1 protein. This invention is designed to decrease glial tumor cell proliferation and improve treatment outcomes for glioma patients. The second patent, "MicroRNA-21 antagonists and its target PDCD4 for use in the treatment of a glioma," focuses on microRNA-21 antagonists and activators of Programmed Cell Death 4. This invention also aims to reduce glial tumor cell proliferation and enhance therapeutic strategies for glioma.

Career Highlights

Mark A Israel is affiliated with Dartmouth College, where he conducts his research and develops his innovative ideas. His work has garnered attention in the scientific community, contributing to advancements in cancer treatment.

Collaborations

Israel collaborates with Arti Gaur, a fellow researcher, to further explore and develop his inventions. Their partnership enhances the potential impact of their work in the field of glioma treatment.

Conclusion

Mark A Israel's contributions to glioma research through his patents demonstrate his commitment to advancing medical science. His innovative approaches hold promise for improving treatment options for patients suffering from this challenging condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…